Heat Biologics Inc(NASDAQ:HTBX) is partnering with OncoSec to develop immunotherapies for cancer fighting treatments. The companies will team up to produce DNA-based remedies that address different stages and types of cancer. Together, they will evaluate and grade the therapies and develop strategies to progress the treatments. OncoSec’s core product is ImmunoPulse, which is still in the investigative stage of its DNA platform development. This will be done with HBTX’s ImPACT immunotherapy platform.
Heat Biologics Inc(NASDAQ:HTBX) is pleased about the agreement as OncoSec is a leader in the DNA delivery field. They are looking to expand their current platform and share research technology in the hopes of furthering both platforms development and revenue generating possibilities. They will also explore other potential applications of each company’s product. Heat’s platform already has two developmental stage programs in effect.
Heat is a clinical-stage biopharmaceutical player that looks to create off-the-shelf products for various types of cancer and its different stages of progression. It also has its viagenpumatcel-L product which is also in Phase 2 trials. This drug addresses lung cancer patients.
The company recently relocated and also expanded its research team at the Research Triangle Park research facility in North Carolina. This was to assist in R&D efforts for Heat Biologics Inc(NASDAQ:HTBX). They also established a clinical advisory board made up of five top-level industry members. This is to assist with the different phases of drug trials. The company also established an advisory committee in Australia in an effort to facilitate cost and time effective measures for recruitment for random clinical trials. Clinical trials are a critical part of drug development and often time’s subjects for study are difficult to locate and recruit.
The stock is starting to build some nice technical features. It has been closing the gap between the 50 and 200 day MA’s. Momentum is strong and it is at year high levels. A break above $7.42 will be the signal for that.